Navigation Links
HemaQuest Pharmaceuticals, Inc. Presents Promising Clinical Results at 52nd Annual Meeting of the American Society of Hematology (ASH)
Date:12/7/2010

evidence of the safety and potential therapeutic activity of HQK-1001 in patients with sickle cell disease and beta thalassemia intermedia. The fetal hemoglobin induction observed in both of the clinical trials is important, given its key role in ameliorating these diseases. Based on these promising clinical results, we plan to initiate a clinical trial testing higher dose levels and longer duration of therapy to more fully characterize the therapeutic potential of HQK-1001 in sickle cell disease."

ABOUT HQK-1001 HQK-1001 belongs to a class of compounds originally discovered at Boston University School of Medicine. These compounds, designated as Short Chain Fatty Acid Derivatives (SCFADs), have been shown to stimulate fetal hemoglobin expression and red blood cell production in the laboratory and in small clinical trials in patients with hemoglobin disorders, including sickle cell disease and beta thalassemia.  Increased fetal hemoglobin production in red blood cells was shown to ameliorate the outcome of patients with these diseases. HQK-1001 is an orally administered SCFAD, which has shown an excellent safety profile and biologic effects on fetal hemoglobin induction and red blood cell production in the laboratory, relevant animal models, and in clinical trials carried out in healthy human subjects as well as patients with sickle cell disease and beta thalassemia. Additionally, the compound has received Orphan Drug Designation in the United States and Europe for both sickle cell disease and beta thalassemia.

ABOUT SICKLE CELL DISEASE AND BETA THALASSEMIASickle cell disease is a genetic blood disorder that affects approximately 80,000 patients in the U.S., and is characterized by production of an abnormal beta hemoglobin chain of adult hemoglobin, which results in distorted, rigid sickle red blood cells, which block blood vessels, causing lack of oxygen to tissues, acute episodes of pain (pain crises), lung injury (acute chest syndrome), a
'/>"/>

SOURCE HemaQuest Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. HemaQuest Announces Appointment of New Executive Management Team; Company Establishes Headquarters in San Diego
2. HemaQuest Pharmaceuticals Raises Additional $4M to Bring Total to $16M in Series B Financing
3. Aires Pharmaceuticals, Inc. Completes $20M Equity Financing and Signs an Option Agreement with a Major Pharmaceutical Company
4. Omthera Pharmaceuticals, Inc. to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
5. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2010 Financial Results
6. DUSA Pharmaceuticals, Inc.® to Host Third Quarter 2010 Corporate Highlights and Financial Results Conference Call
7. Pfizer Commences Tender Offer for All Outstanding Shares of King Pharmaceuticals, Inc.
8. Anadys Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
9. Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase
10. Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX® Phase III Studies for Peyronies Disease
11. Star Scientific Comments on Roskamp Institutes Plans to Conduct Human Alzheimers Clinical Trials Using a Compound (RCP-006) Developed by Rock Creek Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... -- The Association of periOperative Registered Nurses (AORN) has awarded ... Stop and Go Sign designed by Christopher ... M.D., anesthesia providers with Anaesthesia Associates of Massachusetts ... is distributed by the Plexus Management Group, Inc. ... compliance with the AORN Safe Surgery Checklist. ...
(Date:5/5/2015)... , May 5, 2015 Merrimack Pharmaceuticals, ... of a randomized, double-blinded, placebo-controlled Phase 2 clinical ... and ErbB3, in combination with nab-paclitaxel and gemcitabine, ... newly-diagnosed metastatic pancreatic cancer who have high serum ... is the fourth leading cause of cancer death ...
(Date:5/5/2015)... May 5, 2015   Cynosure, Inc. (Nasdaq: ... devices for aesthetic procedures and precision surgical applications worldwide, ... March 31, 2015. First-Quarter Highlights: , ... , Non-GAAP earnings of $0.15 per share; GAAP earnings ... at March 31, 2015 "Cynosure delivered 21 ...
Breaking Medicine Technology:The Preoperative Stop and Go Sign Interactive Checklist Awarded AORN Seal of Recognition 2The Preoperative Stop and Go Sign Interactive Checklist Awarded AORN Seal of Recognition 3Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer 2Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer 3Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer 4Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 2Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 3Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 4Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 5Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 6Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 7Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 8Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 9Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 10Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 11
... today-, SAN CARLOS, Calif., March 17 Nuvelo, ... the Phase 2 program in,catheter occlusion (CO), known as ... Alfimeprase), did not,show sufficient improvement in catheter opening at ... meet the desired target product,profile. As a result, Nuvelo ...
... Findings, BEDMINSTER, N.J., March 17 NPS,Pharmaceuticals, ... top-line,results from a 28-week blinded Phase 3-extension study ... who are dependent,upon parenteral nutrition (PN). The extension ... had completed a 24-week randomized Phase 3 study ...
Cached Medicine Technology:Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development 2Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development 3Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development 4NPS Reports Successful GATTEX(TM) Extension Study 2NPS Reports Successful GATTEX(TM) Extension Study 3NPS Reports Successful GATTEX(TM) Extension Study 4NPS Reports Successful GATTEX(TM) Extension Study 5
(Date:5/5/2015)... York, New York (PRWEB) May 05, 2015 ... lawsuits ( http://www.testosteronelawsuithub.com/ ) filed on behalf ... complications due to their use of prescription ... in the federal multidistrict litigation underway in ... According to court documents dated May 1st, ...
(Date:5/5/2015)... May 05, 2015 From the ... the established leader in enabling enterprise collaboration across ... help customers speed up and simplify the move ... AvePoint Solutions for Office 365 enable ... while ensuring sustainable user adoption and effectively managing ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 Viverae®, ... C.R. Bard Inc., a leading multinational developer, manufacturer ... the fields of vascular, urology, oncology and surgical ... Vanguard Award. The Vanguard Award recognizes outstanding ... wellness programs among Viverae’s significant client base. , ...
(Date:5/5/2015)... York, NY (PRWEB) May 05, 2015 The newly ... on the experiences of Dr. Brad Reedy from his ... Judith Regan was asked why she chose to publish a parenting ... as a parent (and publisher) is the idea that it is ... we and our children are on the trek sometimes together and ...
(Date:5/5/2015)... 2015 Baptist Medical Center Jacksonville’s cancer ... (CoC) of the American College of Surgeons. , To ... more than 30 Commission on Cancer quality care standards, ... and maintain levels of excellence in the delivery of ... to seek care locally at a CoC-accredited cancer center, ...
Breaking Medicine News(10 mins):Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 2Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 3Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 4Health News:AvePoint Unveils New Solutions for Microsoft Office 365 & Azure at Microsoft Ignite 2015 2Health News:AvePoint Unveils New Solutions for Microsoft Office 365 & Azure at Microsoft Ignite 2015 3Health News:Viverae® Honors C. R. Bard, Inc. with 2015 Vanguard Award 2Health News:The Last Parenting Book You Will Ever Need: Veteran Publisher Judith Regan Releases A Provocative New Book By Dr. Brad Reedy, "The Journey Of The Heroic Parent" 2Health News:The Last Parenting Book You Will Ever Need: Veteran Publisher Judith Regan Releases A Provocative New Book By Dr. Brad Reedy, "The Journey Of The Heroic Parent" 3Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 2Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 3Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 4
... research facility in Toronto in Ontario Institute for Cancer ... The new research facility will act as a network ... will consist of // researchers from various Universities ... a team in providing new treatment methods for cancer. ...
... patients with whooping cough/Pertussis have tripled in Idaho (central) and ... infectious respiratory disease. 72 cases have been ... in Ada (55 cases), Boise, Elmore (17) and Valley counties ... are on the rise when compared to the 10 year ...
... published in the December issue of Arthritis and Rheumatism says ... a vital role in the pathogenesis of rheumatoid arthritis (RA), ... protein was found by a team of researchers at the ... of London. It appears that the protein modifies itself and ...
... Researchers at the Virginia Commonwealth University have found that ... periodontitis may be responsible for increasing the risk of ... ,Periodontitis is the inflammation of the supporting tissue that ... presence with a host of diseases including diabetes and ...
... has spread its wings over the Crimean peninsula. The cases have ... in the government as well as public. // ,To ... to determine if the virus is the deadly strain that has ... has been called for by the Ukrainian president in some parts ...
... health sector of England has both doctors and nurses of ... almost 20 percent.// The National Health Service (NHS) of ... Children's Hospital, in the Wellchild awards. ,Jaswant ... has been honoured in a national competition. Children's health charity ...
Cached Medicine News:Health News:Severe Gum Disease Triples Heart Disease Risk 2
... MIRAX SCAN is the system solution for digital ... monitor, a dual processor PC and software modules. ... scanner, which makes the specimens available as Digital ... quality, with the same optical resolution as on ...
... 1400 Series Biosafety Cabinets ... revolutionize working in a ... most comfortable, quiet, and ... cabinet on the market, ...
... Designed for ease of use and patient ... smooth edges for comfort and is available ... to a perfect fit. For hard to ... trach collar to your specifications. Don't just ...
Velcro® Tracheostomy tube holders are available in Adult, pediatric, and infant sizes....
Medicine Products: